Contrast-enhanced ultrasonography of the prostate with sonazoid

Kazuhiro Matsumoto, Ken Nakagawa, Akinori Hashiguchi, Hidaka Kono, Eiji Kikuchi, Hirohiko Nagata, Akira Miyajima, Mototsugu Oya

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective: The diagnosis of prostate cancer is based on the results of ultrasonography-guided needle biopsy of the prostate, but cancer foci are often not visible in conventional transrectal ultrasonography. Sonazoid is a new microbubble contrast agent. The purpose of our study was to compare areas of contrast material enhancement in the prostate at ultrasonography with whole-mount radical prostatectomy specimens to determine if the use of Sonazoid improves the detection rate of prostate cancer. Methods: Fifty patients with biopsy-proven cancer of the prostate who were scheduled to undergo radical prostatectomy were recruited for this study. The day before the operation, each patient was evaluated with ultrasonography at baseline and again during intravenous infusion of Sonazoid. A map of ultrasonography findings was created prospectively at the time of imaging. Following radical prostatectomy, independent mapping of the pathologic results was performed and the maps were compared. Results: Ultrasonography evaluation at baseline demonstrated that at least one focus of cancer was identified in 20 of the 50 subjects (40.0%). Meanwhile at least one cancer focus was enhanced in 31 of the 50 patients (62.0%) when Sonazoid was used. The combination of baseline grayscale imaging and contrast-enhanced imaging allowed identification of at least one focus of cancer in 40 patients (80.0%). Contrast-enhanced ultrasonography can improve sensitivity, especially for the detection of large cancer, peripheral zone cancer and highly malignant cancer. Conclusions: Our study has demonstrated significantly improved detection of prostate cancer with the combination of baseline grayscale imaging and contrast-enhanced imaging compared with conventional ultrasonography techniques only, and this technique may be applicable to targeted biopsy.

Original languageEnglish
Article numberhyq102
Pages (from-to)1099-1104
Number of pages6
JournalJapanese Journal of Clinical Oncology
Volume40
Issue number11
DOIs
Publication statusPublished - 2010 Nov

Fingerprint

Prostate
Ultrasonography
Prostatic Neoplasms
Prostatectomy
Neoplasms
Contrast Media
Biopsy
Microbubbles
Sonazoid
Needle Biopsy
Intravenous Infusions

Keywords

  • Contrast medium
  • Prostate cancer
  • Sonazoid
  • Ultrasonography

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

Contrast-enhanced ultrasonography of the prostate with sonazoid. / Matsumoto, Kazuhiro; Nakagawa, Ken; Hashiguchi, Akinori; Kono, Hidaka; Kikuchi, Eiji; Nagata, Hirohiko; Miyajima, Akira; Oya, Mototsugu.

In: Japanese Journal of Clinical Oncology, Vol. 40, No. 11, hyq102, 11.2010, p. 1099-1104.

Research output: Contribution to journalArticle

Matsumoto, Kazuhiro ; Nakagawa, Ken ; Hashiguchi, Akinori ; Kono, Hidaka ; Kikuchi, Eiji ; Nagata, Hirohiko ; Miyajima, Akira ; Oya, Mototsugu. / Contrast-enhanced ultrasonography of the prostate with sonazoid. In: Japanese Journal of Clinical Oncology. 2010 ; Vol. 40, No. 11. pp. 1099-1104.
@article{f82422978f2548ccb4dfd0fb1f5146ac,
title = "Contrast-enhanced ultrasonography of the prostate with sonazoid",
abstract = "Objective: The diagnosis of prostate cancer is based on the results of ultrasonography-guided needle biopsy of the prostate, but cancer foci are often not visible in conventional transrectal ultrasonography. Sonazoid is a new microbubble contrast agent. The purpose of our study was to compare areas of contrast material enhancement in the prostate at ultrasonography with whole-mount radical prostatectomy specimens to determine if the use of Sonazoid improves the detection rate of prostate cancer. Methods: Fifty patients with biopsy-proven cancer of the prostate who were scheduled to undergo radical prostatectomy were recruited for this study. The day before the operation, each patient was evaluated with ultrasonography at baseline and again during intravenous infusion of Sonazoid. A map of ultrasonography findings was created prospectively at the time of imaging. Following radical prostatectomy, independent mapping of the pathologic results was performed and the maps were compared. Results: Ultrasonography evaluation at baseline demonstrated that at least one focus of cancer was identified in 20 of the 50 subjects (40.0{\%}). Meanwhile at least one cancer focus was enhanced in 31 of the 50 patients (62.0{\%}) when Sonazoid was used. The combination of baseline grayscale imaging and contrast-enhanced imaging allowed identification of at least one focus of cancer in 40 patients (80.0{\%}). Contrast-enhanced ultrasonography can improve sensitivity, especially for the detection of large cancer, peripheral zone cancer and highly malignant cancer. Conclusions: Our study has demonstrated significantly improved detection of prostate cancer with the combination of baseline grayscale imaging and contrast-enhanced imaging compared with conventional ultrasonography techniques only, and this technique may be applicable to targeted biopsy.",
keywords = "Contrast medium, Prostate cancer, Sonazoid, Ultrasonography",
author = "Kazuhiro Matsumoto and Ken Nakagawa and Akinori Hashiguchi and Hidaka Kono and Eiji Kikuchi and Hirohiko Nagata and Akira Miyajima and Mototsugu Oya",
year = "2010",
month = "11",
doi = "10.1093/jjco/hyq102",
language = "English",
volume = "40",
pages = "1099--1104",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Contrast-enhanced ultrasonography of the prostate with sonazoid

AU - Matsumoto, Kazuhiro

AU - Nakagawa, Ken

AU - Hashiguchi, Akinori

AU - Kono, Hidaka

AU - Kikuchi, Eiji

AU - Nagata, Hirohiko

AU - Miyajima, Akira

AU - Oya, Mototsugu

PY - 2010/11

Y1 - 2010/11

N2 - Objective: The diagnosis of prostate cancer is based on the results of ultrasonography-guided needle biopsy of the prostate, but cancer foci are often not visible in conventional transrectal ultrasonography. Sonazoid is a new microbubble contrast agent. The purpose of our study was to compare areas of contrast material enhancement in the prostate at ultrasonography with whole-mount radical prostatectomy specimens to determine if the use of Sonazoid improves the detection rate of prostate cancer. Methods: Fifty patients with biopsy-proven cancer of the prostate who were scheduled to undergo radical prostatectomy were recruited for this study. The day before the operation, each patient was evaluated with ultrasonography at baseline and again during intravenous infusion of Sonazoid. A map of ultrasonography findings was created prospectively at the time of imaging. Following radical prostatectomy, independent mapping of the pathologic results was performed and the maps were compared. Results: Ultrasonography evaluation at baseline demonstrated that at least one focus of cancer was identified in 20 of the 50 subjects (40.0%). Meanwhile at least one cancer focus was enhanced in 31 of the 50 patients (62.0%) when Sonazoid was used. The combination of baseline grayscale imaging and contrast-enhanced imaging allowed identification of at least one focus of cancer in 40 patients (80.0%). Contrast-enhanced ultrasonography can improve sensitivity, especially for the detection of large cancer, peripheral zone cancer and highly malignant cancer. Conclusions: Our study has demonstrated significantly improved detection of prostate cancer with the combination of baseline grayscale imaging and contrast-enhanced imaging compared with conventional ultrasonography techniques only, and this technique may be applicable to targeted biopsy.

AB - Objective: The diagnosis of prostate cancer is based on the results of ultrasonography-guided needle biopsy of the prostate, but cancer foci are often not visible in conventional transrectal ultrasonography. Sonazoid is a new microbubble contrast agent. The purpose of our study was to compare areas of contrast material enhancement in the prostate at ultrasonography with whole-mount radical prostatectomy specimens to determine if the use of Sonazoid improves the detection rate of prostate cancer. Methods: Fifty patients with biopsy-proven cancer of the prostate who were scheduled to undergo radical prostatectomy were recruited for this study. The day before the operation, each patient was evaluated with ultrasonography at baseline and again during intravenous infusion of Sonazoid. A map of ultrasonography findings was created prospectively at the time of imaging. Following radical prostatectomy, independent mapping of the pathologic results was performed and the maps were compared. Results: Ultrasonography evaluation at baseline demonstrated that at least one focus of cancer was identified in 20 of the 50 subjects (40.0%). Meanwhile at least one cancer focus was enhanced in 31 of the 50 patients (62.0%) when Sonazoid was used. The combination of baseline grayscale imaging and contrast-enhanced imaging allowed identification of at least one focus of cancer in 40 patients (80.0%). Contrast-enhanced ultrasonography can improve sensitivity, especially for the detection of large cancer, peripheral zone cancer and highly malignant cancer. Conclusions: Our study has demonstrated significantly improved detection of prostate cancer with the combination of baseline grayscale imaging and contrast-enhanced imaging compared with conventional ultrasonography techniques only, and this technique may be applicable to targeted biopsy.

KW - Contrast medium

KW - Prostate cancer

KW - Sonazoid

KW - Ultrasonography

UR - http://www.scopus.com/inward/record.url?scp=78049438758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049438758&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyq102

DO - 10.1093/jjco/hyq102

M3 - Article

C2 - 20581002

AN - SCOPUS:78049438758

VL - 40

SP - 1099

EP - 1104

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 11

M1 - hyq102

ER -